Neurology Specific Literature Search   
 
[home][thesaurus]
    

Differential
(Click to cross reference)
advances in neurology
adverse drug reaction
algorithm
andexanet
antiarrhythmic drugs
anticoagulant, complications of
anticoagulant, contraindications
anticoagulant, discontinuation
anticoagulant, restarting
anticoagulant, reversal of
anticoagulant, treatment
anticoagulant, treatment in CVD
anticoagulation effect
anticoagulation, perioperative
apixaban
argatroban
arrhythmia, cardiac
aspirin
asymptomatic
atrial appendage closure
atrial fibrillation
atrial fibrillation, nonvalvular
atrial fibrillation, risk stratification
atrial fibrillation, surgical treatment
atrial fibrillation, treatment
atrial flutter
atrial septal defect
bedridden
breast feeding
bridge therapy
bronchoscopy
cancer associated hypercoagulation
cancer, cerebrovascular accident complicating patients with
carcinoma
cardiomyopathy
carotid artery occlusion, intracranial
carotid artery occlusion, perioperative
CAT scan, abnormal
cataract surgery
cerebral embolism
cerebral embolism, cardiac origin
cerebral embolism, mechanical extraction
cerebral infarction
cerebral venous thrombosis
cerebrovascular accident
cerebrovascular accident, acute management of
cerebrovascular accident, cardiac disease causing
cerebrovascular accident, complications with
cerebrovascular accident, cryptogenic
cerebrovascular accident, postoperative
cerebrovascular accident, prevention of
cerebrovascular accident, primary prevention
cerebrovascular accident, recurrent
cerebrovascular accident, secondary prevention
cerebrovascular accident, severity
cerebrovascular accident, thrombolytic agents in treatment
cerebrovascular accident, women
cerebrovascular accident, young adult
CHADS-VaSC score
ciraparantag
clopidogrel
clot retrieval
colonoscopy
compliance
complications
controversies in neurology
cost
cost effectiveness
coumarin
coumarin, restarting treatment
coumarin, stopping treatment
cryoablation
dabigatran
dabigatran, dose
deafness, unilateral
delivery, complicated
dental procedure, neurologic complications with
dialysis
drug interactions
dural sinus thrombosis
dyspepsia
edoxaban
efficacy
electromyogram
embolic stroke of unknown source
embolism, systemic
endoscopic surgery
endoscopy
endovascular therapy
enoxaparin
evidence-based research
factor Xa inhibitor
falling
fibrinolytic agents
fibrinolytic agents, complications
fibrinolytic agents, contraindications
fibrinolytic agents, intra-arterial local infusion
fibrinolytic therapy, selection criteria
gastrointestinal bleeding
HAS-BLED score
head injury
headache
heart valve, prosthetic
hemorrhagic diathesis
hemostatic therapy
heparin
heparin, low-molecular-weight
heparinoid, low molecular weight
hepatic failure
hip arthroplasty
Holter monitoring
hormone replacement
hormone therapy
iatrogenic neurologic disorders
idarucizumab
incidental finding
INR value, time in range
INR values
intracerebral hemorrhage
intracerebral hemorrhage, progression of
intracerebral hemorrhage, silent
intracerebral hemorrhage, treatment of
intracerebral hemorrhage, volume
intracranial hemorrhage
labor, complicated
left atrial appendage, percutaneous closure
left ventricular dysfunction
liver disease
liver function enzymes
menopause
MERCI trial
microhemorrhage, intracerebral
middle cerebral artery, occlusion of
mimics
misdiagnosis
mortality
MRI, abnormal
myocardial infarction
neurologic complications of, surgery
neuroradiology, interventional
NIH stroke scale
non-vitamin K antagonist oral anticoagulants
non-vitamin K antagonist oral anticoagulants, coagulation test
number needed to treat
old age, neurology of
oral contraceptives
oral contraceptives, cerbrovascular disease and
ovarian induction
pacemaker, cardiac-transvenous
partial thromboplastin time
patent foramen ovale, surgical treatment of
patient information and support
peri-procedural
platelet inhibiting drugs
platelet inhibiting drugs, combined
platelet inhibiting drugs, discontinuation
postoperative neurologic complications
practice guidelines
pregnancy, neurologic complications in
prevention of neurologic disorders
prognosis
prothrombin complex concentrate
prothrombin time
prothrombin time, prolonged
radiofrequency ablation
rapid thromboelasticity
recanalization, arterial
recurrent
RELY trial
renal failure
reperfusion
RESPECT trial
review article
risk factors
risk factors, modification
risk stratification
risk-benefit assessment
rivaroxaban
ROCKET - AF trial
safety
serum alanine aminotransferase
solitaire device
SPORTIF trial
stent, carotid artery
subarachnoid hemorrhage
subarachnoid hemorrhage, cerebral convexity
subdural hematoma
T lesion of MCA-ICA
teratogenesis
teratogenic drugs
thrombectomy
thrombin inhibitor
thrombolysis, mechanical
thrombophlebitis
thrombus, mural
tissue plasminogen activator, intravenous
transient ischemic attack
transient neurologic deficit
transluminal angioplasty, coronary artery
transurethral prostatectomy
trauma
treatment of neurologic disorder
venous thrombosis, non-cerebral
vitamin K
vitamin K antagonist
Watchman device
ximelagatran
Showing articles 250 to 300 of 865 << Previous Next >>

Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis
NEJM 373:1418-1428, Kappos, L.,et al, 2015

Disorders of the Nervous System Caused by Drugs, Toxins, and Chemical Agents, Monoamine Oxidase Inhibitors
Adams & Victors Principles of Neurology Chp 43, pg 1210, Ropper, A.H.,et al, 2014

Disorders of the Nervous System Caused by Drugs, Toxins, and Chemical Agents, Serotonin Reuptake Inhibitors and Related Drugs
Adams & Victors Principles of Neurology Chp 43, pg 1212, Ropper, A.H.,et al, 2014

Disturbances of Cerebrospinal Fluid, Including Hydrocephalus, Pseudotumor Cerebri, and Low-Pressure Syndromes, Pseudotumor Cerebri
Adams & Victors Principles of Neurology, Chp 30, pg 628, Ropper, A.H.,et al, 2014

Infections of the Nervous System, (Bacterial, Fungal, Spirochetal, Parasitic) and Sarcoidosis, Sarcoidosis
Adams & Victors Principles of Neurology, Chp 32, pg 721, Ropper, A.H.,et al, 2014

Degenerative Diseases of the Nervous System, Alzheimer Disease
Adams & Victors Principles of Neurology, Chp 39, pg 1063, Ropper, A.H.,et al, 2014

Prosopometamorphopsia and Facial Hallucinations
Lancet 384:1998, Blom, J.D.,et al, 2014

Treatment of Relapsing-Remitting Multiple Sclerosis After 24 Doses of Natalizumab
JAMA Neurol 71:954-960, Clerico, M.,et al, 2014

Treatment of Primary CNS Vasculitis with Rituximab: Case Report
Neurol 82:1287-1288, Salvarani, C.,et al, 2014

Obsessive-Compulsive Disorder
BMJ 348:g2183, Veale, D.,et al, 2014

Fibromyalgia
JAMA 311:1547-1555, Clauw, D.J., 2014

Anti-HMGCR Autoantibodies in European Patients with Autoimmune Necrotizing Myopathies
Medicine 93:150-157, Allenbach, Y.,et al, 2014

Long-Term Effectivenss of Dopamine Agonists and Monoamine Oxidase B Inhibitors Compared with Levodopa as Initial Treatment for Parkinsons Disease (PD MED): A Large, Open-Label, Pragmatic Randomised Trial
Lancet 383: Doi: 10.1016/S0140-6736, PD MED Collaborative Group, 2014

Inhibition of Serotonin Reuptake by Antidepressants and Cerebral Microbleeds in the General Population
Stroke 45:1951-1957, Aarts, N.,et al, 2014

Effect of Rituximab in Patients with Leucine-Rich, Glioma-Inactivated 1 Antibody-Associated Encephalopathy
JAMA Neurol 71:896-900, Irani, S.R.,et al, 2014

Daclizumab-Induced Adverse Events in Multiple Organ Systems in Multiple Sclerosis
Neurol 82:984-988, Oh, J.,et al, 2014

Effect of high-dose Simvastatin on Brain Atrophy and Disability in Secondary Progressive Multiple Sclerosis (MS-STAT): A Randomised, Placebo-Controlled, Phase 2 Trial
Lancet 383:2213-2221, Chataway, J.,et al, 2014

Antiamyloid Therapy for Alzheimers Disease - Are We on the Right Road?
NEJM 370:377-378, Karran, E. & Hardy, J., 2014

Mystery Case: A 63-year-old Man with Progressive Proximal Pain and Weakness
Neurol 82:e26-e29, Scripko, P.D.,et al, 2014

Effect of Citalopram on Agitation in Alzheimer Disease The CitAD Randomized Clinical Trial
JAMA 311:682-691, Porsteinsson, A.P.,et al, 2014

Bevacizumab in Glioblastoma - Still Much to Learn
NEJM 370:764-765, Fine, H.A., 2014

Safety and Efficacy of Ofatumumab in Relapsing-Remitting Multiple Sclerosis
Neurol 82:573-581, Sorensen, P.S.,et al, 2014

Serotonin Syndrome
BMJ 348:g1626, Buckley, N.A.,et al, 2014

Sarcoidosis Presenting as Longitudinally Extensive Myelitis
Neurol 81:e61, Goenka, N. & Venna N., 2013

Aggressive Medical Therapy Alone is Not Adequate in Certain Patients with Severe Symptomatic Carotid Stenosis
Stroke 44:2955-2956, Brown, M.M., 2013

Aggressive Medical Therapy Alone is Adequate in Certain Patients with Severe Symptomatic Carotid Stenosis
Stroke 44:2957-2958, Chaturvedi, S.,et al, 2013

Reduction in Early Stroke Risk in Carotid Stenosis with Transient Ischemic Attack Associated with Statin Treatment
Stroke 44:2814-2820, Merwick, A.,et al, 2013

Adult Attention Deficit - Hyperactivity Disorder
NEJM 369:1935-1944, Volkow, N.D. & Swanson, J.M., 2013

Daclizumab High-Yield Process in Relapsing-Remitting Multiple Sclerosis (SELECT): A Randomised, Double-Blind, Placebo-Controlled Trial
Lancet 381:2167-2175, Gold, R.,et al, 2013

Statin Therapy should not be Discontinued in Patients with Intracerebral Hemorrhage
Stroke 44:2060-2061,2062, Bustamante, A. & Montaner, J., 2013

Statin Therapy should be Discontinued in Patients with Intracerebral Hemorrhage
Stroke 44:2058-2059,2062, Goldstein, L., 2013

Daclizumab High-Yield Process in Relapsing-Remitting Multiple Sclerosis (SELECT): A Randomised, Double-Blind, Placebo-Controlled Trial
Lancet 381:190-194, Gold, R.,et al, 2013

Tumor Necrosis Factor-Alpha Inhibitors: An Overview of Adverse Effects
UpToDate January, Stone, J.H., 2013

Tumor Necrosis Factor-Alpha Inhibitors: Risk of Malignancy
UpToDate January, Stone, J.H., 2013

Varicella-Zoster Virus Acute Myelitis in a Patient with MS Treated with Natalizumab
Neurol 80:1812-1813, Yeung, J.,et al, 2013

Should Statins be Paused or Discontinued After Thrombolysis or Acute Intracerebral Hemorrhage? No!
Stroke 44:1472-1476, Scheitz, J.F.,et al, 2013

Proton Pump Inhibitor and Histamine 2 Receptor Antagonist Use and Vitamin B12 Deficiency
JAMA 310:2435-2442, Lam, J.R.,et al, 2013

The Spectrum of Statin Myopathy
Curr Opin Rheumatol 25:747-752, Mohassel, P. & Mammen, A.L., 2013

Neurological Immune-Related Adverse Events of Ipilimumab
Pract Neurol 13:278-280, Bot, I.,et al, 2013

Herpes Encephalitis During Natalizumab Tretament in Multiple Sclerosis
Mult Scler J 18:909-911, Kwiatkowski, A.,et al, 2012

Persistent Diffusion-Restricted Lesions in Bevacizumab-Treated Malignant Gliomas are Associated with Improved Survival Compared with Matched Controls
AJNR 33:1763-1770, Mong, S.,et al, 2012

Fatal Varicella-Zoster Virus Vasculopathy Associated with Adalimumab Therapy
Arch Neurol 69:1193-1196, Baek, W.,et al, 2012

Myasthenia Gravis
BMJ 345:e8497, Spillane, J.,et al, 2012

High-Dose Statins should be Used in All Acute Ischemic Strokes
Stroke 43:1992-1993, 1996, Moonis, M., 2012

High-Dose Statins Should Only Be Used in Atherosclerotic Strokes
Stroke 43:1994-1995,1996, Furie, K.L., 2012

Selective Serotonin Reuptake Inhibitors May be Helpful in Most Patients with Stroke
Stroke 43:3150-3151,3154, Chollet, F., 2012

Should Every Patient with Stroke be on Selective Serotonin Reuptake Inhibitors?
Stroke 43:3152-3153,3154, Marshall, R.S., 2012

Dropped Head Syndrome: Report of Three Cases During Treatment with a Mek Inhibitor
Neurol 79:1929-1932, Chen, X.,et al, 2012

Severe Relapses under Fingolimod Treatment Prescribed after Natalizumab
Neurol 79:2004-2006,1942, Centonze, D.,et al, 2012

PML-IRIS in a patient treated with Brentuximab
Neurol 79:2075-2077, Geldern, G.,et al, 2012



Showing articles 250 to 300 of 865 << Previous Next >>